Vivesto

Board/Management Information • Nov 7, 2025

Nomination Committee appointed for the Annual General Meeting 2026 in Vivesto

In accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB's ("Vivesto") Annual General Meeting in 2025, it is hereby announced that the Nomination Committee for the Annual General Meeting 2026 has been appointed, based on the ownership structure as per 30 September 2025.

The Nomination Committee for the 2026 Annual General Meeting comprises the following members:

• Per Arwidsson, appointed by Arwidsro,
• Christer Hasslebäck, representing own holdings, and
• Peter Zonabend, Chairman of the Board of Vivesto.

Per Arwidsson has been appointed Chairman of the Nomination Committee.

Vivesto's Annual General Meeting will be held on 7 May 2026 in Stockholm.

Shareholders who wish to submit proposals to the Nomination Committee for the Annual General Meeting 2026 may send them by e-mail to nomination@vivesto.com. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted no later than 31 January 2026.

For further information, please contact:

Peter Zonabend, Chairman of the Board of Vivesto

Phone: 018-50 54 40 E-mail: IR@vivesto.com

About Vivesto AB

Vivesto is a Swedish development company that aims to offer new treatment options for hard-totreat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.

Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

Attachments

Nomination Committee appointed for the Annual General Meeting 2026 in Vivesto